Opening book details…
Can I read Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial on EtoBox?
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial by Kim A. Connelly; C. David Mazer; Pankaj Puar; Hwee Teoh; Chao-Hung Wang; Tamique Mason; Farhad Akhavein; Ching-Wen Chang; Min-Hui Liu; Ning-I Yang; Wei-Siang Chen; Yu-Hsiang Juan; Erika Opingari; Yaseen Salyani; William Barbour; Aryan Pasricha; Shamon Ahmed; Andrew Kosmopoulos; Raj Verma; Michael Moroney; Ehab Bakbak; Aishwarya Krishnaraj; Deepak L. Bhatt; Javed Butler; Mikhail N. Kosiborod; Carolyn S.P. Lam; David A. Hess; Otavio Rizzi Coelho-Filho; Myriam Lafreniere-Roula; Kevin E. Thorpe; Adrian Quan; Lawrence A. Leiter; Andrew T. Yan; Subodh Verma is a Medicine article available to read on EtoBox.
What is Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial about?
## Background: Sodium-glucose cotransporter 2 inhibitors have been demonstrated to promote reverse cardiac remodeling in people with diabetes or heart failure. Although it has been theorized that sodium-glucose cotransporter 2 inhibitors might afford similar benefits in people without diabetes or prevalent heart failure, this has not been evaluated. We sought to determine whether sodium-glucose cotransporter 2 inhibition with empagliflozin leads to a decrease in left ventricular (LV) mass in people without type 2 diabetes or significant heart failure. ## Methods: Between April 2021 and January 2022, 169 individuals, 40 to 80 years of age, without diabetes but with risk factors for adverse cardiac remodeling were randomly assigned to empagliflozin (10 mg/d; n=85) or placebo (n=84) for 6 months. The primary outcome was the 6-month change in LV mass indexed (LVMi) to baseline body surface area as measured by cardiac magnetic resonance imaging. Other measures included 6-month changes in LV end-diastolic and LV end-systolic volumes indexed to baseline body surface area and LV ejection fraction. ## Results: Among the 169 participants (141 men [83%]; mean age, 59.3±10.5 years), baseline L
Who reads Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Kim A. Connelly; C. David Mazer; Pankaj Puar; Hwee Teoh; Chao-Hung Wang; Tamique Mason; Farhad Akhavein; Ching-Wen Chang; Min-Hui Liu; Ning-I Yang; Wei-Siang Chen; Yu-Hsiang Juan; Erika Opingari; Yaseen Salyani; William Barbour; Aryan Pasricha; Shamon Ahmed; Andrew Kosmopoulos; Raj Verma; Michael Moroney; Ehab Bakbak; Aishwarya Krishnaraj; Deepak L. Bhatt; Javed Butler; Mikhail N. Kosiborod; Carolyn S.P. Lam; David A. Hess; Otavio Rizzi Coelho-Filho; Myriam Lafreniere-Roula; Kevin E. Thorpe; Adrian Quan; Lawrence A. Leiter; Andrew T. Yan; Subodh Verma
- Publisher
- Ovid Technologies (Wolters Kluwer Health)
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)